Latest Headlines

Latest Headlines

Stem cell work points to new approach on fighting obesity

Investigators at Queen Mary University of London say that by regulating the length of primary cilia on stem cells they could prevent them from turning into fat cells--a possible new direction in obesity research.

Peptide could play a role in preventing binge eating, obesity

Shifting focus from the hypothalamus to the amygdala, investigators at Boston University say that an injection of a peptide and hormone reduced appetite in an experimental model, pointing to a new approach to treating obesity and binge eating.

Obesity player USGI raises $19.5M to complete U.S. pivotal trial, FDA submission

USGI Medical expects that its latest infusion of $19.5 million in cash and debt will enable it to complete a U.S. pivotal trial and to submit for FDA approval. The pivotal trial is currently in the follow-up phase; the financing will also enable a crossover study of patients who previously had received sham treatment in the trial.

Novo hopes for European Saxenda launch this year after CHMP nod

Novo Nordisk's obesity therapy Saxenda is on a roll. Just over a month after snagging FDA approval, the drug scored a positive recommendation on Thursday from Europe's Committee for Medicinal Products for Human Use (CHMP). But by the time it gets to the regulatory finish line, the med may have some competition on the continent.

Obesity devices aim for the U.S. as Obalon gets $30M to complete pivotal trial in 2015, EnteroMedics gains FDA approval

Micro cap EnteroMedics is up 35% in early trading on the news that it has garnered an FDA approval for its Maestro vagal blocking therapy as an obesity treatment. The device was narrowly supported by a June FDA panel due to concerns about efficacy. In addition, another obesity device company, Obalon Therapeutics, has secured $30 million to complete a U.S. pivotal trial in 2015 for its nonsurgical weight loss balloon.

Zafgen's promising obesity drug comes through in another midstage trial

Zafgen charted a third major victory for its in-development obesity drug, spurring weight loss for patients who have endured brain injuries and stoking hopes for success in Phase III.

Novo Nordisk kick-starts its obesity franchise with a long-awaited FDA nod

Two months after its self-imposed deadline, the FDA finally signed off on Novo Nordisk's first weight-loss therapy, a milestone for the company as it blueprints a future in obesity.

Contrave demand swamps Takeda's direct-delivery discount program

Private insurers and public payers have refused to cover obesity drugs--or foisted big copays onto patients--dragging down new drugs. So, when Takeda rolled out Orexigen's new obesity drug Contrave a few weeks ago, the Japanese drugmaker also rolled out a direct-delivery program, Direct Save.

Novo Nordisk builds blockbuster case with promising PhIII obesity data

In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as it works to build a portfolio of such treatments.

ReShape finally reveals pivotal obesity data ahead of FDA review

ReShape Medical said about a year ago that it had positive U.S. pivotal obesity data for its ReShape Integrated Dual Balloon. Now it has offered a glimpse of that data for the first time, ahead of an FDA review that's expected to come during the first half of 2015.